欢迎访问《现代生物医学进展》编辑部！

目的：探讨哌拉西林舒巴坦与莫西沙星联用治疗社区获得性肺炎的临床效果。方法：随机选取2015 年3 月--2016 年3 月在我院呼吸科病区住院的90 例社区获得性肺炎患者，并随机分为观察组(28 例)、对照A组(31 例)对照B 组(31 例)。观察组患者采用哌拉西林舒巴坦粉针3.75 g，bid，联合莫西沙星0.4 g，静脉注射，qd，对照A 组患者则单用哌拉西林舒巴坦粉针3.75 g，静脉滴注，bid，对照B 组患者采用单用莫西沙星0.4 g，静脉注射，qd，三组患者的治疗时间均为10 d。治疗结束后，比较两组患者的临床症状改善情况及不良反应的发生情况。结果：治疗10 天后，观察组患者治疗后肺部浸润性阴影、肺部啰音、胃肠道情况及体温等均显著好转，观察组患者的临床治疗有效情况显著高于对照A 组（100% vs 87.09%，P<0.05），对照B 组的有效率也较A 组提高（96.77%vs 87.09%，P>0.05）。观察组总体治愈率显著高于对照A 组（92.86%vs 51.61%）,对照B 组的总体治愈率显著高于对照A 组（70.97%vs 51.61%）, 但观察组和对照B 组之间并无显著性差异（p>0.05）。观察组、对照A 组、对照B组的细菌清除率分别为 92.86%、74.19%、90.32%，观察组和对照B组的清除率显著高于对照A组；三组的不良反应发生率比较并无显著性差异(P>0.05)。结论：哌拉西林舒巴坦联合莫西沙星治疗社区获得性肺炎的效果显著优于单用哌拉西林舒巴坦治疗的效果，稍优于单用莫西沙星的治疗效果，安全性较高。

英文摘要:

Objective:To analyze the therapeutic effect of Piperacillin Sulbactam combined with Moxifloxacin on Community acquired pneumonia (CAP).Methods:90 cases of CAP admitted in our hospital from March 2015 to March 20163 were randomly divided into the experimental group(28 cases) and control group A(31 cases) and B(31 cases). Patients in the experimental group were administered by intravenous infusion of Piperacillin Sulbactam 375 mg/250 mL, bid and Moxifloxacin, 40 mg/250 mL, qd, Patients in control A group were administered by intravenous infusion of Piperacillin Sulbactam, 375 mg/250 mL.bid. Patients in control B group were administered by intravenous infusion by Moxifloxacin, 40 mg/250 mL, qd. All of the three groups were treated for 10 days respectively. The therapeutic effect and the recurrence rate (ADR) were compared among the three groups after 10 days.Results:The effective rate of experimental group was significantly higher than that of control groupA (96.77%vs 87.09%)(P<0.05). and comparison between experimental group and control B group was not obviously (100%vs 96.77%) (P>0.05), and control B group have significant effective rate than control A group. Lung shadow, Lung rales, Tem disorder, as uncomfort have significant improvement of both experimental group and control B group. The bacteria clearance rate of experimental group, control A group and control B are 92.86%， 74.19%, 90.32% respectively. And bacteria clearance rate of experimental group and Control B group are higher than control A group significantly (p<0.05), and there is no significant difference between control B group and experimental group. But the ADR among the three groups were not obvious, they are 3.57%, 3.23%，6.45% respectively (P>0.05).Conclusion:The therapeutic effects of the combination of Piperacillin Sulbactam and Moxifloxacin were better than Piperacillin Sulbactam significantly and better than Moxifloxacin a little. And the ADR of the three group were low.

View Full Text View/Add Comment Download reader